Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2020 Feb 6

PMID 32019275

Citations 18

Authors

Christine Rangger

Roland Haubner

Affiliations

Soon will be listed here.

Abstract

This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.

Citing Articles

Imaging of Peripheral Intraneural Tumors: A Comprehensive Review for Radiologists.

Shirodkar K, Hussein M, Reddy P, Shah A, Raniga S, Pal D Cancers (Basel). 2025; 17(2).

PMID: 39858028 PMC: 11763772. DOI: 10.3390/cancers17020246.

Ultrasound-Assisted Solid-Phase Affibody Synthesis Using Z as an Example-Superior to the Conventional Protocol?.

Prochiner M, Judmann B, Ruder A, Wangler B, Schirrmacher R, Wangler C Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458921 PMC: 11510254. DOI: 10.3390/ph17101280.

Hetero-Diels-Alder and CuAAC Click Reactions for Fluorine-18 Labeling of Peptides: Automation and Comparative Study of the Two Methods.

Maujean T, Ramanoudjame S, Riche S, Le Guen C, Boisson F, Muller S Molecules. 2024; 29(13).

PMID: 38999148 PMC: 11243578. DOI: 10.3390/molecules29133198.

Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.

Badenhorst M, Windhorst A, Beaino W Front Med (Lausanne). 2024; 11:1401515.

PMID: 38915766 PMC: 11195831. DOI: 10.3389/fmed.2024.1401515.

Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides.

Saxena T, Sie C, Lin K, Ye D, Saatchi K, Hafeli U Pharmaceutics. 2022; 14(12).

PMID: 36559303 PMC: 9780892. DOI: 10.3390/pharmaceutics14122809.

References

Mease R, Dusich C, Foss C, Ravert H, Dannals R, Seidel J . N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14(10):3036-43. PMC: 3078104. DOI: 10.1158/1078-0432.CCR-07-1517. View

Wieser G, Mansi R, Grosu A, Schultze-Seemann W, Dumont-Walter R, Meyer P . Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics. 2014; 4(4):412-9. PMC: 3936293. DOI: 10.7150/thno.7324. View

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018; 45(9):1636-1644. PMC: 6061489. DOI: 10.1007/s00259-018-4015-2. View

Becaud J, Mu L, Karramkam M, Schubiger P, Ametamey S, Graham K . Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution. Bioconjug Chem. 2009; 20(12):2254-61. DOI: 10.1021/bc900240z. View

Schottelius M, Poethko T, Herz M, Reubi J, Kessler H, Schwaiger M . First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004; 10(11):3593-606. DOI: 10.1158/1078-0432.CCR-03-0359. View

Mayerhoefer M, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S . [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. Invest Radiol. 2018; 53(7):403-408. DOI: 10.1097/RLI.0000000000000469. View

Dubash S, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K . Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. J Nucl Med. 2016; 57(8):1207-13. DOI: 10.2967/jnumed.115.169532. View

Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M . Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med. 2006; 47(4):566-73. View

Waldmann C, Stuparu A, van Dam R, Slavik R . The Search for an Alternative to [Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of F-labeled Somatostatin Analog Development. Theranostics. 2019; 9(5):1336-1347. PMC: 6401503. DOI: 10.7150/thno.31806. View

10.

Kaeopookum P, Petrik M, Summer D, Klinger M, Zhai C, Rangger C . Comparison of Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. Nucl Med Biol. 2019; 78-79:1-10. DOI: 10.1016/j.nucmedbio.2019.09.002. View

11.

Kang C, Sun X, Jia F, Song H, Chen Y, Lewis M . Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy. Bioconjug Chem. 2012; 23(9):1775-82. PMC: 3447103. DOI: 10.1021/bc200696b. View

12.

Valverde I, Vomstein S, Mindt T . Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting. J Med Chem. 2016; 59(8):3867-77. DOI: 10.1021/acs.jmedchem.6b00025. View

13.

Chen H, Niu G, Wu H, Chen X . Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics. 2016; 6(1):78-92. PMC: 4679356. DOI: 10.7150/thno.13242. View

14.

Arumugam S, Chin J, Schirrmacher R, Popik V, Kostikov A . [18F]azadibenzocyclooctyne ([18F]ADIBO): a biocompatible radioactive labeling synthon for peptides using catalyst free [3+2] cycloaddition. Bioorg Med Chem Lett. 2011; 21(23):6987-91. DOI: 10.1016/j.bmcl.2011.09.126. View

15.

Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen C . First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics. 2015; 5(12):1303-16. PMC: 4615734. DOI: 10.7150/thno.12956. View

16.

de Aguiar Ferreira C, Fuscaldi L, Townsend D, Rubello D, de Barros A . Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed Pharmacother. 2017; 87:58-72. PMC: 5331929. DOI: 10.1016/j.biopha.2016.12.083. View

17.

Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hanscheid H . [Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics. 2017; 7(9):2350-2362. PMC: 5525741. DOI: 10.7150/thno.19119. View

18.

Dietlein F, Hohberg M, Kobe C, Zlatopolskiy B, Krapf P, Endepols H . An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2019; 61(2):202-209. DOI: 10.2967/jnumed.119.229542. View

19.

de Jong M, Bakker W, Krenning E, Breeman W, van der Pluijm M, Bernard B . Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24(4):368-71. DOI: 10.1007/BF00881807. View

20.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher D, Liu S . microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005; 46(10):1707-18. View